April 2020 PMID 32064793

Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.

Victor Sokolov, Tatiana Yakovleva, Lulu Chu, Weifeng Tang, Peter J Greasley, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W Boulton, Robert C Penland

Download social card

Mentions

Peak: 1 in Feb 2020

across 2 sources since Feb 2020

Extended reach

22,194

potential audience

Total likes

1,125

Video views

18,348

Mentions per month

Feb 2020 – Nov 2025

Where it's discussed

X / Twitter3 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions mainly reference the study directly and include technical hashtags, suggesting a neutral stance with moderate interest; the tone remains informational, with little debate or emotional engagement, though the mention of different drugs indicates some recognition of their significance in research.

AgreementNeither agree nor disagree

Most discussions focus on identifying the differences in SGLT1 inhibition among the drugs but don't clearly agree or disagree with the findings; they seem neutral.

InterestModerate interest

The discussions show mild curiosity, primarily signaling technical interest through hashtags and mentions, but lack enthusiasm or detailed critique.

EngagementNeutral engagement

Participants mention the study and its methods briefly, indicating centered engagement without deep analysis or critique.

ImpactModerate impact

Given the technical focus with limited elaboration, the discussions hint at some relevance but don't demonstrate a widespread perception of immediate high impact.

Abstract in brief

The study used a quantitative systems pharmacology model to compare how well canagliflozin, dapagliflozin, and empagliflozin inhibit the sodium-glucose cotransporters SGLT 1 and 2 in type 2 diabetes patients.
Results showed that dapagliflozin and empagliflozin have similar effects on glucose excretion, whereas canagliflozin also inhibits SGLT1 and contributes an additional approximately 10% to daily urinary glucose excretion at approved doses.
The differences in drug effects were mainly driven by variations in filtered glucose levels observed across clinical studies, highlighting that canagliflozin's unique SGLT1 inhibition distinguishes it from the other two medications.

Read the full abstract

All mentions

Breakthrough Findings on Anti Aging and Cardiovascular Health

Ryker Black reveals findings from a double-blind trial that identifies a revolutionary anti-aging pill, influencing aging processes significantly. The study highlights empagliflozin's positive impact on cardiovascular…

The Anti Aging Channel · Nov 2, 2025 18,348 views

Terry Maratos-Flier

@Maratosflier · X

@ChristosArgyrop @mikejohansenmd @VijayanMD @Charbel_Khoury @kdjhaveri https://t.co/oHGZ9x8Foi

Feb 14, 2021 · 2,566 followers View post →

Rosa for QSP

@RosaQSP · X

Apr 7, 2020 · 2 likes · 640 followers View post →